---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000465"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:38:20.358109+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Eledon prioritizes kidney transplant program for tegoprubart; Phase 1b data expected Q1 2023

## Summary
- Ph 1b kidney transplant trial enrollment ongoing; initial 3- and 6-month data at World Congress of Nephrology March 2023.
- FDA cleared IND for Phase 2 BESTOW trial (tegoprubart vs tacrolimus, ~120 patients); site initiation mid-2023.
- Deprioritizing tegoprubart in IgAN and discontinuing islet cell trial to focus resources on kidney transplantation.
- Cash resources sufficient to fund operating activities into 2024 (no specific amount given).
- Collaboration with eGenesis for preclinical xenotransplantation studies using tegoprubart.

## SEC filing metadata
- accession: 0000950170-23-000465
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000095017023000465/0000950170-23-000465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000095017023000465/eldn-20230109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000465
- JSON: https://secwatch.observer/filing/0000950170-23-000465.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000465.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.